Trial Profile
P53MVA and Pembrolizumab in Treating Patients With Recurrent Ovarian, Primary Peritoneal, or Fallopian Tube Cancer
Status:
Active, no longer recruiting
Phase of Trial:
Phase II
Latest Information Update: 05 Jan 2024
Price :
$35
*
At a glance
- Drugs MVA-p53 (Primary) ; Pembrolizumab (Primary)
- Indications Carcinoma; Fallopian tube cancer; Ovarian cancer; Peritoneal cancer
- Focus Therapeutic Use
- 02 Jan 2024 Planned End Date changed from 6 Dec 2023 to 30 Mar 2024.
- 02 Jan 2024 Planned primary completion date changed from 6 Dec 2023 to 30 Mar 2024.
- 28 Sep 2022 Status changed from recruiting to active, no longer recruiting.